P667: LONG-TERM EFFICACY OF ACALABRUTINIB-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND HIGHER-RISK GENOMIC FEATURES: POOLED ANALYSIS OF CLINICAL TRIAL DATA
M. Davids,
J. Sharman,
P. Ghia,
J. Woyach,
W. Jurczak,
T. Siddiqi,
P. Miranda,
M. Shahkarami,
T. Yu,
U. Emeribe,
J. Byrd
Affiliations
M. Davids
1 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
J. Sharman
2 Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States of America
P. Ghia
3 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
J. Woyach
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States of America
W. Jurczak
5 Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland
T. Siddiqi
6 City of Hope Comprehensive Cancer Center, Duarte, California
P. Miranda
7 AstraZeneca, Gaithersburg, Maryland
M. Shahkarami
8 AstraZeneca, South San Francisco, California
T. Yu
8 AstraZeneca, South San Francisco, California
U. Emeribe
7 AstraZeneca, Gaithersburg, Maryland
J. Byrd
9 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America
